Sponsor:
Jacobio Pharmaceuticals Co., Ltd.
Code:
NCT05002270
Conditions
Advanced Solid Tumor
NSCLC
CRC
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
JAB-21822 (KRAS G12C inhibitor)
JAB-21822 (KRAS G12C inhibitor)
JAB-21822 (KRAS G12C inhibitor)
Cetuximab (EGFR inhibitor)
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Jacobio Pharmaceuticals Co., Ltd. on 2023-09-07.